NZ590747A - Cycloalkylidene and heterocycloalkylidene hdac inhibitor compounds - Google Patents

Cycloalkylidene and heterocycloalkylidene hdac inhibitor compounds

Info

Publication number
NZ590747A
NZ590747A NZ590747A NZ59074709A NZ590747A NZ 590747 A NZ590747 A NZ 590747A NZ 590747 A NZ590747 A NZ 590747A NZ 59074709 A NZ59074709 A NZ 59074709A NZ 590747 A NZ590747 A NZ 590747A
Authority
NZ
New Zealand
Prior art keywords
cyclopropyl
compound
disease
heterocycloalkylidene
cycloalkylidene
Prior art date
Application number
NZ590747A
Other languages
English (en)
Inventor
Lawrence S Melvin
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of NZ590747A publication Critical patent/NZ590747A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ590747A 2008-07-28 2009-07-28 Cycloalkylidene and heterocycloalkylidene hdac inhibitor compounds NZ590747A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8408108P 2008-07-28 2008-07-28
PCT/US2009/051964 WO2010014611A1 (en) 2008-07-28 2009-07-28 Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds

Publications (1)

Publication Number Publication Date
NZ590747A true NZ590747A (en) 2012-11-30

Family

ID=40996551

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ590747A NZ590747A (en) 2008-07-28 2009-07-28 Cycloalkylidene and heterocycloalkylidene hdac inhibitor compounds

Country Status (11)

Country Link
US (2) US8088771B2 (enExample)
EP (1) EP2326622A1 (enExample)
JP (2) JP2011529504A (enExample)
KR (1) KR20110038159A (enExample)
CN (1) CN102123987A (enExample)
AU (1) AU2009276699A1 (enExample)
BR (1) BRPI0916713A2 (enExample)
CA (1) CA2731323A1 (enExample)
MX (1) MX2011001090A (enExample)
NZ (1) NZ590747A (enExample)
WO (1) WO2010014611A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2170882A1 (en) * 2007-06-26 2010-04-07 Gilead Colorado, Inc. Imidazopyridinyl thiazolyl histone deacetylase inhibitors
TW200922564A (en) * 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
NZ602832A (en) 2008-07-14 2014-04-30 Gilead Sciences Inc Fused heterocyclic hdac inhibitor compounds
AU2009271003A1 (en) * 2008-07-14 2010-01-21 Gilead Sciences, Inc. Imidazolylpyrimidine compounds as HDAC and/or CDK inhibitors
CA2728228A1 (en) * 2008-07-14 2010-01-21 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
AU2009276699A1 (en) 2008-07-28 2010-02-04 Gilead Sciences, Inc. Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds
JP2012501344A (ja) 2008-08-29 2012-01-19 トレヴェンティス コーポレイション アミロイド症を治療する組成物及び方法
AU2009289649B2 (en) 2008-09-03 2016-05-05 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
ES2463826T3 (es) 2009-06-08 2014-05-29 Gilead Sciences, Inc. Compuestos inhibidores de HDAC de cicloalquilcarbamato benzamida anilina
KR20120031170A (ko) * 2009-06-08 2012-03-30 길리애드 사이언시즈, 인코포레이티드 알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
US8938950B2 (en) * 2010-09-30 2015-01-27 Electro-Motive Diesel, Inc. Turbocharger mixing manifold for an exhaust aftertreatment system for a locomotive having a two-stroke locomotive diesel engine
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
JP6250403B2 (ja) 2011-02-28 2017-12-20 バイオマリン ファーマシューティカル インク ヒストン脱アセチル化酵素阻害剤
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
CN102838625B (zh) * 2011-06-22 2015-04-15 中国科学院上海药物研究所 四氢吡啶并噻唑类化合物、其制备方法、包含该化合物的药物组合物及其用途
US9173402B2 (en) 2011-07-15 2015-11-03 Basf Se Fungicidal alkyl-substituted 2[2-chloro-4-(4-chioro-phenoxy)-phenyl]-1[1,2,4]triazol-1-yl-ethanol compounds
WO2013010894A1 (en) 2011-07-15 2013-01-24 Basf Se Fungicidal phenylalkyl-substituted 2-[2-chloro-4-(4-chloro-phenoxy)-phenyl]-1-[1,2,4]triazol-1-yl-ethanol compounds
AU2012296887A1 (en) 2011-08-15 2014-01-30 Basf Se Fungicidal substituted 1-{2-[2-halo-4-(4-halogen-phenoxy)-phenyl]-2-alkoxy-3-methyl-butyl}-1H-[1,2,4]triazole compounds
MX2014001671A (es) 2011-08-15 2014-05-27 Basf Se Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]- 2-aluiniloxi-etil}-1h[1,2,4]triazol sustituidos.
MX2014000511A (es) 2011-08-15 2014-02-19 Basf Se Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]- 2-etoxi-etil}-1h-[1,2,4]triazol sustituidos.
US11007194B2 (en) 2011-11-11 2021-05-18 Array Biopharma Inc. Method of treating a proliferative disease
WO2013078264A1 (en) 2011-11-23 2013-05-30 Novartis Ag Pharmaceutical formulations
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
PT2970139T (pt) 2013-03-15 2018-08-01 Biomarin Pharm Inc Inibidores de hdac
TWI624467B (zh) 2013-10-14 2018-05-21 衛材Ｒ＆Ｄ企管股份有限公司 選擇性經取代之喹啉化合物
US9663486B2 (en) 2013-10-14 2017-05-30 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
US10660890B2 (en) 2013-10-24 2020-05-26 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr) Treatment of polycystic diseases with an HDAC6 inhibitor
US9567322B2 (en) 2014-10-31 2017-02-14 Abbvie S.Á.R.L. Substituted tetrahydropyrans and method of use
KR102549606B1 (ko) * 2017-01-10 2023-06-29 씨스톤 파마슈티컬즈 (쑤저우) 컴퍼니 리미티드 Hdac6 선택적 억제제 및 이의 제조방법과 응용
WO2019027855A1 (en) * 2017-08-02 2019-02-07 Merck Sharp & Dohme Corp. NOVEL SUBSTITUTED PHENYL COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO)
JP7250422B2 (ja) * 2017-12-28 2023-04-03 東京応化工業株式会社 レジスト組成物、及びレジストパターン形成方法
JP7377207B2 (ja) * 2018-01-29 2023-11-09 メルク パテント ゲーエムベーハー Ｇｃｎ２阻害剤およびその使用
EP3930746A4 (en) 2019-02-25 2023-03-15 Emory University CHIMERA COMPOUNDS AND METHODS FOR MANAGEMENT OF NEUROLOGICAL DISORDERS OR CONDITIONS

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE264833T1 (de) 1996-01-16 2004-05-15 Bristol Myers Squibb Co Konformationseingeschränkte aromatische inhibitoren des microsomalen triglyceridtransferproteins und verfahren
US20040006011A1 (en) * 1996-07-12 2004-01-08 Gour Barbara J. Peptidomimetic modulators of cell adhesion
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US5760246A (en) * 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
DE60040676D1 (de) 1999-09-17 2008-12-11 Millennium Pharm Inc BENZAMIDE UND ÄHNLICHE INHIBITOREN VON FAKTOR Xa
AU2001231154A1 (en) 2000-01-24 2001-07-31 Adherex Technologies Inc. Peptidomimetic modulators of cell adhesion
AU2001234689A1 (en) 2000-02-01 2001-08-14 Cor Therapeutics, Inc. Bivalent phenylene inhibitors of factor xa
US6403588B1 (en) * 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
AU2001252609A1 (en) 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd. Imidazopyridine derivatives
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
AU2002214626A1 (en) 2000-09-29 2002-04-08 Cor Therapeutics, Inc. Quaternary amines and related inhibitors of factor xa
AU2001295992A1 (en) 2000-10-24 2002-05-06 Sankyo Company Limited Imidazopyridine derivatives
US7429599B2 (en) 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
US7129242B2 (en) 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
SE0100569D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab New compounds
BR0207096A (pt) 2001-02-20 2004-01-20 Astrazeneca Ab Uso de um composto, compostos, formulação farmacêutica, e, método de tratamento e/ou profilaxia de condições associadas com a inibição de glicogênio sintase quinase-3
EP1383799A4 (en) 2001-04-10 2008-08-06 Transtech Pharma Inc PROBES, SYSTEMS AND METHODS FOR DISCOVERING MEDICAMENTS
HUP0400266A2 (hu) 2001-06-21 2004-08-30 Smithkline Beecham Corp. Imidazo[1,2-a]piridin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk herpeszvírus-fertőzések megelőzésére vagy kezelésére
CA2450555A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
EP1270551A1 (en) 2001-06-26 2003-01-02 Aventis Pharma Deutschland GmbH Urea derivatives with antiproteolytic activity
US7868204B2 (en) * 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
WO2003031446A1 (en) 2001-10-05 2003-04-17 Smithkline Beecham Corporation Imidazo-pyridine derivatives for use in the treatment of herpes viral infection
DE60225316T2 (de) 2001-11-13 2009-02-26 AXYS Pharmaceuticals, Inc., South San Francisco Cyanoalkylamino-derivate als protease-hemmer
US6995144B2 (en) 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
JP2003313126A (ja) 2002-04-23 2003-11-06 Sankyo Co Ltd イミダゾピリジン誘導体を有効成分とする医薬
JP2004002826A (ja) 2002-04-24 2004-01-08 Sankyo Co Ltd 高分子イミダゾピリジン誘導体
US20040034084A1 (en) 2002-05-24 2004-02-19 Celgene Corporation Methods for using JNK inhibitors for treating or preventing disease-related wasting
GB0212049D0 (en) 2002-05-24 2002-07-03 Merck Sharp & Dohme Therapeutic agents
CA2388358A1 (en) 2002-05-31 2003-11-30 Voiceage Corporation A method and device for multi-rate lattice vector quantization
JP3725105B2 (ja) * 2002-08-30 2005-12-07 株式会社東芝 二次電池の過放電防止回路及び二次電池の過放電防止法
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
EP1551795A1 (en) 2002-10-17 2005-07-13 Methylgene, Inc. Inhibitors of histone deacetylase
US20040087642A1 (en) 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
US20040092568A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods for the treatment, prevention and management of macular degeneration
KR20050084027A (ko) 2002-11-28 2005-08-26 쉐링 악티엔게젤샤프트 Ｃｈｋ-, ｐｄｋ- 및 ａｋｔ-억제성 피리미딘, 그의제조방법 및 약제로서의 그의 용도
US20050019366A1 (en) 2002-12-31 2005-01-27 Zeldis Jerome B. Drug-coated stents and methods of use therefor
TW200418806A (en) * 2003-01-13 2004-10-01 Fujisawa Pharmaceutical Co HDAC inhibitor
TW200424174A (en) 2003-02-06 2004-11-16 Hoffmann La Roche New TP diamide
US7208491B2 (en) 2003-02-07 2007-04-24 Hoffmann-La Roche Inc. N-monoacylated o-phenylenediamines
WO2004076452A1 (en) 2003-02-26 2004-09-10 Merck Sharp & Dohme Limited 5,8-DIFLUOROIMIDAZO[1,2-a]PYRIDINES AS GABA-A α2/α3 LIGANDS FOR TREATING ANXIETY AND/OR DEPRESSION
US7320989B2 (en) * 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
EP1603900A4 (en) 2003-03-06 2008-08-20 Merck & Co Inc IMIDAZOPYRIDIN COMPOUNDS WITH EFFECT AGAINST PROTOZOEN
PL1611088T3 (pl) 2003-04-07 2009-11-30 Pharmacyclics Inc Hydroksamiany jako środki terapeutyczne
US20050187266A1 (en) 2003-04-15 2005-08-25 Pfizer Inc Alpha substituted carboxylic acids
EA200501462A1 (ru) 2003-04-15 2006-04-28 Пфайзер Инк. Альфа-замещенные карбоновые кислоты в качестве модуляторов ppar
US20050234066A1 (en) * 2004-04-15 2005-10-20 Agouron Pharmaceuticals, Inc. Alpha substituted carboxylic acids
EP1628666B1 (en) 2003-05-14 2015-09-23 NeuroGenetic Pharmaceuticals, Inc. Compouds and uses thereof in modulating amyloid beta
WO2005006945A2 (en) 2003-07-03 2005-01-27 The Salk Institute For Biological Studies Methods for treating neural disorders and compounds useful therefor
CA2539117A1 (en) 2003-09-24 2005-04-07 Methylgene Inc. Inhibitors of histone deacetylase
CA2744997A1 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and method of use
KR20060124610A (ko) 2003-11-06 2006-12-05 셀진 코포레이션 석면-관련된 질환 또는 장애를 치료 및 관리하기 위하여ｊｎｋ 억제제를 사용하는 방법 및 이 물질을 포함하는조성물
US7524851B2 (en) 2003-12-05 2009-04-28 Robert Bosch Gesellschaft Fur Medizinische Forschung (Rbmf) Diagnostic methods for therapeutic compounds and methods for monitoring azathioprine therapy
US7429590B2 (en) 2003-12-10 2008-09-30 Merck & Co. Inc. Antiprotozoal imidazopyridine compounds
US7671181B2 (en) 2004-01-16 2010-03-02 Merck Sharp & Dohme Corp. Polynucleotides encoding coccidian parasite casein kinase I, a chemotherapeutic target for antiprotozoal agents
WO2005077368A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
DE102004008141A1 (de) 2004-02-19 2005-09-01 Abbott Gmbh & Co. Kg Guanidinverbindungen und ihre Verwendung als Bindungspartner für 5-HT5-Rezeptoren
US20070093492A1 (en) * 2004-03-09 2007-04-26 Weir-Torn Jiaang Pyrrolidine derivatives
US7253204B2 (en) * 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
EP1735319B1 (en) * 2004-03-26 2017-05-03 MethylGene Inc. Inhibitors of histone deacetylase
MXPA06012130A (es) 2004-04-20 2007-01-31 Transtech Pharma Inc Derivados de tiazol y pirimidina substituidos como moduladores del receptor de melanocortina.
WO2005102318A1 (en) 2004-04-20 2005-11-03 Ab Science Use of c-kit inhibitors for treating hiv related diseases
WO2005102325A1 (en) 2004-04-20 2005-11-03 Ab Science Use of c-kit inhibitors for treating inflammatory muscle disorders including myositis and muscular dystrophy
WO2005102326A2 (en) 2004-04-23 2005-11-03 Ab Science Use of c-kit inhibitors for treating renal diseases
EP1758654A1 (en) 2004-04-23 2007-03-07 AB Science Use of c-kit inhibitors for treating plasmodium related diseases
CA2564574A1 (en) 2004-04-23 2005-11-03 Ab Science Use of c-kit inhibitors for treating fibrosis
BRPI0511267A (pt) * 2004-05-17 2007-11-27 Tibotec Pharm Ltd 1,5-diidropirido[3,2-b]indol-2-onas 4-substituìdas
US20070249628A1 (en) 2004-05-18 2007-10-25 Alain Moussy Use of Mast Cells Inhibitors for Treating Patients Exposed to Chemical or Biological Weapons
WO2005115304A2 (en) 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating fibrodysplasia
WO2005115385A1 (en) 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating acne
PL1781639T3 (pl) 2004-07-28 2012-07-31 Janssen Pharmaceutica Nv Podstawione pochodne indolilo-alkiloaminowe jako nowe inhibitory deacetylazy histonowej
WO2006038001A1 (en) 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
AU2005295734A1 (en) 2004-10-15 2006-04-27 Biogen Idec Ma Inc. Methods of treating vascular injuries
CA2588558A1 (en) 2004-11-23 2006-06-01 Celgene Corporation Jnk inhibitors for treatment of cns injury
CA2588517A1 (en) 2004-12-01 2006-06-08 Devgen N.V. 5-carboxamido substituted thiazole derivatives that interact with ion channels, in particular with ion channels from the kv family
US20090099160A1 (en) 2004-12-17 2009-04-16 David Andrews 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors
WO2006070943A1 (ja) 2004-12-28 2006-07-06 Takeda Pharmaceutical Company Limited 縮合イミダゾール化合物およびその用途
WO2006077401A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Pyrrolopyridines useful in the treatment of inflammation
AU2006223508A1 (en) * 2005-03-09 2006-09-21 Merck Frosst Canada Ltd Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use
US20060223807A1 (en) 2005-03-29 2006-10-05 University Of Massachusetts Medical School, A Massachusetts Corporation Therapeutic methods for type I diabetes
JP2008537748A (ja) 2005-04-06 2008-09-25 エクセリクシス、インコーポレイテッド ｃ−Ｍｅｔモジュレーター及び使用方法
SG159561A1 (en) 2005-05-09 2010-03-30 Achillion Pharmaceuticals Inc Thiazole compounds and methods of use
JP4528918B2 (ja) 2005-06-21 2010-08-25 学校法人 関西大学 カルボキサミド誘導体
MA28394B1 (fr) * 2005-06-24 2007-01-02 Genelabs Tech Inc Derives d'heteroaryle pour traitement des virus
US7309787B2 (en) 2005-07-13 2007-12-18 Allergan, Inc. Kinase inhibitors
EP1904065A2 (en) 2005-07-14 2008-04-02 AB Science Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma
US20100069387A1 (en) 2005-09-07 2010-03-18 Palmer Stephen S IKK Inhibitors for the Treatment of Endometriosis
WO2007037187A1 (ja) 2005-09-27 2007-04-05 Shionogi & Co., Ltd. Ｐｇｄ２受容体アンタゴニスト活性を有するスルホンアミド誘導体
WO2007036732A1 (en) 2005-09-30 2007-04-05 Astrazeneca Ab Imidazo [1,2-a] pyridine having anti-cell-proliferation activity
AR058073A1 (es) 2005-10-03 2008-01-23 Astrazeneca Ab Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos
ITMI20060296A1 (it) 2006-02-17 2007-08-18 Alberto Lodolo Dispositivo di intercettazione multifunzionale
EP1996233A2 (en) 2006-02-27 2008-12-03 Gilead Colorado, Inc. Combinations comprising a histone deacetylase inhibiting agent and a nuclear hormone receptor ligand for treating cardiovascular conditions
CA2649861A1 (en) 2006-04-26 2007-11-08 Merck & Co., Inc. Disubstituted aniline compounds
EP2170882A1 (en) * 2007-06-26 2010-04-07 Gilead Colorado, Inc. Imidazopyridinyl thiazolyl histone deacetylase inhibitors
NZ602832A (en) * 2008-07-14 2014-04-30 Gilead Sciences Inc Fused heterocyclic hdac inhibitor compounds
AU2009271003A1 (en) * 2008-07-14 2010-01-21 Gilead Sciences, Inc. Imidazolylpyrimidine compounds as HDAC and/or CDK inhibitors
AU2009276699A1 (en) 2008-07-28 2010-02-04 Gilead Sciences, Inc. Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds
KR20120031170A (ko) * 2009-06-08 2012-03-30 길리애드 사이언시즈, 인코포레이티드 알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물
ES2463826T3 (es) * 2009-06-08 2014-05-29 Gilead Sciences, Inc. Compuestos inhibidores de HDAC de cicloalquilcarbamato benzamida anilina

Also Published As

Publication number Publication date
WO2010014611A1 (en) 2010-02-04
US20120045412A1 (en) 2012-02-23
CA2731323A1 (en) 2010-02-04
AU2009276699A1 (en) 2010-02-04
BRPI0916713A2 (pt) 2015-11-10
US8088771B2 (en) 2012-01-03
US20100022543A1 (en) 2010-01-28
EP2326622A1 (en) 2011-06-01
US8198299B2 (en) 2012-06-12
CN102123987A (zh) 2011-07-13
MX2011001090A (es) 2011-03-15
JP2011529504A (ja) 2011-12-08
KR20110038159A (ko) 2011-04-13
JP2014098002A (ja) 2014-05-29

Similar Documents

Publication Publication Date Title
US11970481B1 (en) Substituted pyridine derivatives as SARM1 inhibitors
WO2010009139A3 (en) Imidazolylpyrimidine compounds as hdac and / or cdk inhibitors
NZ596863A (en) Alkanoylamino benzamide aniline hdac inhibitor compounds
WO2010009155A3 (en) Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
IL198979A (en) Enzyme inhibitors diacylglycerol o-acetyltransferase type 1
WO2010139180A8 (zh) 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
WO2010046445A3 (en) Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use
NZ596783A (en) Cycloalkylcarbamate benzamide aniline hdac inhibitor compounds
TW200714600A (en) Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications
EP3241822B1 (en) Urat1 inhibitor
US20080188524A1 (en) Methods of treating pain
PH12013500879A1 (en) Crystalline forms of hydrochloride salt of (4a-r,9a-s) -1- (1h - benzoimidazole- 5 -carbonyl) -2, 3, 4, 4a, 9, 9a - hexahydro -1h- indeno [2, 1 -b] pyridine- 6 -carbonitrile and their use as hsd 1 inhibitors
WO2007089857A3 (en) Substituted imidazole derivatives and their use as ptpase inhibitors
PL1656348T4 (pl) Pochodne acetylenu jako inhibitory deacetylazy histonowej
WO2004092115A3 (en) Hydroxamates as therapeutic agents
WO2007097931A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2009030952A3 (en) Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway
TW200716648A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
WO2008130320A3 (en) Novel n- (8-heteroaryltetrahydronaphtalene-2yl) or n- (5- heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
NZ602191A (en) Heterocyclic amides as rock inhibitors
WO2007140005A3 (en) Oxazolyl piperidine modulators of fatty acid amide hydrolase
MX2009011276A (es) Inhibidor de dpp-iv que incluye el grupo beta-amino, metodo para la preparacion del mismo y composicion farmaceutica que contiene el mismo para prevenir y tratar una diabetes o una obesidad.
MX2013008213A (es) N-[3-(5-amino-3,3a,7,7a-tetrahidro-1h-2,4-dioxa-6-aza-inden-7-il) -fenil]-amidas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2).
MX2009012765A (es) Moduladores de urea con heteroarilo sustituido de acido graso amida hidrolasa.
EA201001414A1 (ru) Производные азетидина и их применение

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: GILEAD SCIENCES, INC., US

Free format text: OLD OWNER(S): GILEAD SCIENCES, INC.; LAWRENCE S MELVIN; MICHAEL GRAUPE; CHANDRASEKAR VENKATARAMANI; JUAN A GUERRERO

S883 Correction of error according to section 88(3) (mistake in register caused on part of patentee or applicant)

Free format text: CORRECTION TO TITLE (54)

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 28 JUL 2016 BY COMPUTER PACKAGES INC

Effective date: 20130726

LAPS Patent lapsed